Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines on July 22, 2025 Acquisition Homo sapiens Metapneumovirus Molecular Clamp technology non-mRNA vaccine Respiratory syncytial virus respiratory vaccines RSV sanofi vaccine pipeline Vaccines, Combined Vicebio +
Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application on May 22, 2025 Biologics License Application Clinical Trials COVID19 (disease) Effectiveness Influenza Moderna mRNA-1083 Prices United States Food and Drug Administration Vaccines Vaccines, Combined +